• Jaguar Health posted net income of USD 8.72 million, swinging from a net loss a year earlier, as revenue climbed 815.6% to USD 20.27 million.
• License revenue rose to USD 19.04 million, while product revenue fell 44.5% to USD 1.2 million on lower Mytesi sales volume.
• Operating expenses slipped 13.3% to USD 10.09 million, led by a 64.1% drop in sales and marketing expense to 896,000.
• The quarter included a January 2026 licensing deal with Woodward Specialty, an affiliate of Future Pak, making it the exclusive marketer for Mytesi and Canalevia-CA1 in the US; Jaguar received USD 16 million upfront with another USD 2 million tied to post-closing conditions.
• Cash totaled USD 7.3 million at March 31, 2026, while management said the January licensing fees improved liquidity but did not remove substantial doubt about its ability to continue as a going concern for one year from the financial statements’ issuance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-232560), on May 20, 2026, and is solely responsible for the information contained therein.